Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B

Brazilian Journal of Infectious Diseases

Volumn 16, Issue 1, 2012, Pages 9-14

  Li, Feng ^a   Zhu, Chang Lai ^a   Zhang, Hong ^a   Huang, Hua ^a   Wei, Qun ^a   Zhu, Xiang ^a   Cheng, Xiao Yang ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Cirrhosis; Hepatitis B, chronic; Hyaluronic acid; Laminin; Liver; ROC curve

Indexed keywords

HYALURONIC ACID; LAMININ;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD DONOR; BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; HYALURONIC ACID BLOOD LEVEL; LAMININ BLOOD LEVEL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHINA; FEMALE; HEPATITIS B, CHRONIC; HUMANS; HYALURONIC ACID; LAMININ; LIVER CIRRHOSIS; MALE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84863043841     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(12)70267-2     Document Type: Article

References (34)

1. Parsian H., Rahimipour A., Nouri M., et al. Serum hyaluronic acid and laminin as biomarkers in liver fibrosis. J Gastrointestin Liver Dis 2010, 19(2):169-174.
2. Li C., Wan M., Zeng M., et al. A preliminary study of the combination of noninvasive parameters in the diagnosis of liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 2001, 9(5):261-263.
3. Ueki N., Taguchi T., Takahashi M., et al. Inhibition of hyaluronan synthesis by vesnarinone in cultured human myofibroblasts. Biochim Biophys Acta 2000, 1495(2):160-167.
4. Apte M., Haber P., Darby S., et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut 1999, 44(4):534-541.
5. Hepatology 2002, 36(5 Suppl 1):S3-S20. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.
6. Dienstag J.L. The role of liver biopsy in chronic hepatitis C. Hepatology 2002, 36(5 Suppl 1):S152-S160.
7. Resino S., Bellón J.M., Asensio C., et al. Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/hepatitis C coinfected patients?. BMC Infect Dis 2010, 10:244.
8. Lee H.H., Seo Y.S., Um S.H., et al. Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease. J Korean Med Sci 2010, 25(1):67-74.
9. Oliveri F., Coco B., Ciccorossi P., et al. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol 2008, 14(40):6154-6162.
10. Zheng M., Cai W.M., Weng H.L., Liu R.H. ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis. World J Gastroenterol 2002, 8(6):1073-1076.
11. Tao J., Peng H., Cai W., Dong F., Weng H., Liu R. Influence factors of serum fibrosis markers in liver fibrosis. World J Gastroenterol 2003, 9(11):2497-2500.
12. Manning D.S., Afdhal N.H. Diagnosis and quantitation of fibrosis. Gastroenterology 2008, 134(6):1670-1681.
13. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38(2):518-526.
14. Carey E., Carey W.D. Noninvasive tests for liver disease, fibrosis, and cirrhosis: Is liver biopsy obsolete?. Cleve Clin J Med 2010, 77(8):519-527.
15. Friedrich-Rust M., Rosenberg W., Parkes J., Herrmann E., Zeuzem S., Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010, 10:103.
16. Guéchot J., Loria A., Serfaty L., Giral P., Giboudeau J., Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol 1995, 22(1):22-26.
17. Timpl R., Rohde H., Robey P.G., Rennard S.I., Foidart J.M., Martin G.R. Laminin - a glycoprotein from basement membranes. J Biol Chem 1979, 254(19):9933-9937.
18. Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol 2008, 32(6 Suppl 1):52-57.
19. Halfon P., Bourlière M., Pénaranda G., et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005, 4:6.
20. Niemelä O., Risteli J., Blake J.E., Risteli L., Compton K.V., Orrego H. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990, 98(6):1612-1619.
21. Körner T., Kropf J., Gressner A.M. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996, 25(5):684-688.
22. Geramizadeh B., Janfeshan K., Saberfiroozi M. Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B. Saudi J Gastroenterol 2008, 14(4):174-177.
23. Montazeri G., Estakhri A., Mohamadnejad M., et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 2005, 5:32.
24. Murawaki Y., Ikuta Y., Okamoto K., Koda M., Kawasaki H. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol 2001, 36(6):399-406.
25. Guéchot J., Serfaty L., Bonnand A.M., Chazouillères O., Poupon R.E., Poupon R. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol 2000, 32(3):447-452.
26. Leroy V., De Traversay C., Barnoud R., et al. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha. J Hepatol 2001, 35(1):120-126.
27. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24(2):289-293.
28. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39(4):561-577.
29. Pinzani M., Rombouts K., Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005, 42(Suppl1):S22-S36.
30. Grzeszczuk A., Prokopowicz D. Serum hyaluronic acid during lamivudine treatment in chronic hepatitis B. Rocz Akad Med Bialymst 2004, 49:275-279.
31. Swets J.A. Measuring the accuracy of diagnostic systems. Science 1988, 240(4857):1285-1293.
32. Shi H.B., Fu J.F., Wang C.L. Clinical value of hepatic fibrosis parameters and serum ferritin in obese children with nonalcoholic fatty liver disease. Zhejiang Da Xue Xue Bao Yi Xue Ban 2008, 37(3):245-249.
33. Santos V.N., Leite-Mór M.M., Kondo M., et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005, 38(5):747-753.
34. Bolarin D.M., Azinge E.C. Biochemical markers, extracellular components in liver fibrosis and cirrhosis. Nig Q J Hosp Med 2007, 17(1):42-52.